Geeta Hampson

Prof. Geeta Hampson


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2012 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
STS. Thambiah
S. Thambiah
RRR. Roplekar
R. Roplekar
PMP. Manghat
P. Manghat
IFI. Fogelman
I. Fogelman
WFW. D. Fraser
W. D. Fraser
GHGeeta Hampson
Geeta Hampson

6 September 2011 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
SSSunita K Sandhu
Sunita K Sandhu
GHGeeta Hampson
Geeta Hampson
With an increasingly ageing population, osteoporosis and osteoporosis-related fractures is fast becoming an important public health problem placing a considerable economic burden on health service resources. This does not account for the substantial pain, disability and indeed mortality incurred after a fracture, particularly a hip fracture. Osteoporosis is a systemic skeletal disorder which results from an imbalance in bone remodeling. This leads to a reduction in bone strength and increased susceptibility to fracture. It affects up to 1 in 2 women and 1 in 5 men. In the past 2 decades, there have been significant advances in bone biology which have helped in the understanding of the pathogenesis of osteoporosis and have led to improved therapies. In developing strategies for fracture prevention, it is important to identify those individuals with the highest fracture risk who will require pharmacological intervention. Treatment is aimed at fracture prevention and includes modification of general lifestyle factors which have been linked to fractures in epidemiological studies and ensuring optimum calcium and vitamin D intake as adjunct to active anti-fracture therapy. A number of drugs are now approved for the treatment of osteoporosis. This review article will describe the pathogenesis of osteoporosis and focus on the methods currently in use for the identification of patients at high fracture risk and will highlight their usefulness and limitations. The existing anti-fracture pharmacotherapies and those in development will be reviewed. Assessment of their effectiveness including the use of biochemical markers of bone turnover in this clinical context will be reviewed.

1 September 2013 in Bone
Verified
Journal Article
Closed access
GHGeeta Hampson
Geeta Hampson
SESylvie Edwards
Sylvie Edwards
SCSoraya Conroy
Soraya Conroy
GBGlen M. Blake
Glen M. Blake
IFIgnac Fogelman
Ignac Fogelman
MFMichelle L. Frost
Michelle L. Frost

7 September 2014 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
SIS. Ishtiaq
S. Ishtiaq
IFI. Fogelman
I. Fogelman
GHGeeta Hampson
Geeta Hampson

9 July 2008 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
MFMichelle L. Frost
Michelle L. Frost
RGRodolpho Grella
Rodolpho Grella
SMSandrine C. Millasseau
Sandrine C. Millasseau
BJBen-Yu Jiang
Ben-Yu Jiang
GHGeeta Hampson
Geeta Hampson
PCPhil J. Chowienczyk
Phil J. Chowienczyk
Arterial calcification leading to increased arterial stiffness, a powerful risk factor for cardiovascular disease, may underlie the association of osteoporosis with cardiovascular disease in postmenopausal women. Osteoprotegerin (OPG), an indirect inhibitor of osteoclastogenesis, may be involved in arterial calcification. We examined relationships between calcification of subclinical atherosclerotic plaque and arterial stiffness with bone mineral density (BMD) and OPG in a group of 54 postmenopausal women referred for routine osteoporosis screening by dual-energy X-ray absorptiometric scanning of the lumbar spine and hip. Presence of calcified and noncalcified plaque in carotid and femoral arteries was examined using ultrasonography. Pulse wave velocity (PWV), a measure of arterial stiffness, was determined by sequential tonometry over the carotid and femoral region. Fifty-nine percent of osteoporotic women had calcified (echogenic) plaque at one or more sites compared with 42% and 20% for women with osteopenia and normal BMD, respectively (P = 0.04). There was a significant negative correlation between PWV and hip BMD (r = −0.35, P = 0.01), which remained significant when age, mean arterial pressure, and serum lipids were taken into account (P = 0.05). No significant relationships were observed between serum concentrations of OPG and lumbar spine or total hip BMD or with the number of arterial sites with calcified or noncalcified plaque. However, there was a strong correlation between OPG and PWV (r = 0.44, P = 0.001), which remained significant when adjusted for age (P = 0.01). These findings suggest that decreased BMD is associated with arterial calcification and stiffening and raise the possibility that OPG is a marker of arterial stiffening, independent of any association with BMD.

9 December 2009 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
PMP. Manghat
P. Manghat
WFW. D. Fraser
W. D. Fraser
AWA. S. Wierzbicki
A. S. Wierzbicki
IFI. Fogelman
I. Fogelman
DGD. J. Goldsmith
D. J. Goldsmith
GHGeeta Hampson
Geeta Hampson